14th April 2026
Company promotes Peggy Hansen to Chief Innovation & Strategy Officer and welcomes Aaron Kendrick as Senior Vice President of Operations
Regenity Biosciences, a global leader in regenerative medicine and contract development and manufacturing partner for the medical device industry, today announced two significant executive appointments that reflect the company’s accelerating growth trajectory and its commitment to building the leadership infrastructure necessary to scale its innovation platform. Effective today, Peggy Hansen has been promoted to Chief Innovation & Strategy Officer, and Aaron Kendrick has joined the company as Senior Vice President of Operations.
Together, these appointments reinforce Regenity’s position as a premier partner for medtech companies seeking differentiated bioresorbable solutions — anchored by a market-leading product portfolio across multiple segments and continued commitment to proprietary product innovation.
Promotion of Peggy Hansen — Chief Innovation & Strategy Officer
Peggy Hansen has been promoted to Chief Innovation & Strategy Officer in recognition of her extraordinary contributions to Regenity over more than 24 years with the company. In this newly created executive role, Peggy will chart Regenity’s innovation agenda and long-term strategic direction — advancing its core platforms in collagen, bioceramics, and synthetic polymers while identifying the complementary technologies, partnerships, and acquisitions that will define the company’s next chapter.
Over the course of her career at Regenity, Peggy has held leadership roles across regulatory, quality, clinical, and commercial functions, most recently leading the company’s contract development and manufacturing business as General Manager. She brings an unmatched depth of knowledge of Regenity’s technologies, deep relationships across its customer base, and a genuine passion for advancing regenerative medicine.
“Peggy’s promotion reflects both the extraordinary depth of her contribution to this company and the strategic importance of this role as we enter our next phase of growth,” said Shawn McCarthy, Chief Executive Officer of Regenity Biosciences. “Her clarity of vision for where regenerative medicine is headed — and how Regenity is positioned to lead — makes her exactly the right person to help shape what comes next.”
“I am deeply honored to step into this role at such a pivotal moment for Regenity and for the field of regenerative medicine,” said Peggy. “Having spent nearly 25 years helping to grow this company across so many functions, I have never been more excited about what lies ahead. Our technology platforms, our manufacturing capabilities, and our pipeline of proprietary technologies give us an exceptional foundation from which to lead. I look forward to helping translate that foundation into the next generation of solutions that make a material difference for patients and for our partners.”
Appointment of Aaron Kendrick — Senior Vice President of Operations
Regenity Biosciences also announced the appointment of Aaron Kendrick as Senior Vice President of Operations. A seasoned operations executive with 25 years of experience in the medical device and life sciences industry, Aaron joins Regenity from Johnson & Johnson Vision where he served Vice President, End-to-End Supply Chain, with accountability for a $1B global business spanning manufacturing, sourcing and distribution across the U.S., Europe and Latin America. He holds a Bachelor of Science in Materials Engineering from Brown University.
In this role, Aaron will oversee Regenity’s manufacturing operations, supply chain, and quality systems across the company’s facilities in Paramus, Oakland, and Allendale, New Jersey (NJ), as well as its manufacturing location in Groningen, the Netherlands. His appointment comes at a critical inflection point for the company, which currently produces more than five million devices annually for medical technology clients worldwide and is actively scaling its operations, including the opening of a new facility in Allendale (NJ).
“Bringing Aaron on board is a direct investment in our ability to deliver today and at the scale we are actively building toward,” said Shawn McCarthy. “As our pipeline advances and our commercial footprint broadens, operational excellence becomes a true competitive advantage. Aaron’s track record of building and scaling high-performance operations in demanding regulated environments is the exact experience we need, and we are thrilled to welcome him to the Regenity team.”
“Regenity has built something genuinely differentiated through a manufacturing platform with deep materials expertise, strong regulatory credentials, and a pipeline of proprietary products that address unmet clinical needs,” said Aaron. “I am excited to join this team and to help build the operational infrastructure that allows Regenity to deliver on the inspirational promise of its technology for partners and the patients we serve.”